Physician profile
Zacharia Reda
NPI 1487658936
$1,402.68
in general payments reported to CMS, 2019-2025
19 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $84.30 · 2021: $365 · 2022: $86.77 · 2023: $213 · 2024: $361 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $386.68 | 2019-2025 | Nucala, Bexsero, Rotarix |
| Astrazeneca Pharmaceuticals LP | $348.42 | 2019-2024 | Fasenra |
| Pfizer INC. | $185.97 | 2021-2025 | |
| Cranial Technologies, INC | $96.25 | 2021-2025 | Doc Band |
| Sanofi Pasteur INC. | $81.96 | 2023-2024 | |
| Incyte Corporation | $55.12 | 2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $27.36 | 2025 | |
| Merck Sharp & Dohme LLC | $26.99 | 2021-2023 | Vaxneuvance, Gardasil 9, Rotateq |
| Alk-Abello, INC | $24.57 | 2024 | Odactra, Grastek, Ragwitek |
| Ceribell, INC. | $24.41 | 2025 | Pocket Eeg Device |
| Verrica Pharmaceuticals INC. | $23.42 | 2025 | Ycanth |
| Becton, Dickinson and Company | $21.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.26 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $19.10 | 2022 | |
| Abbvie INC. | $18.34 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $17.72 | 2019 | |
| Tris Pharma INC | $14.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zacharia Reda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.